Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: A Chinese consensus statement

Clinical Microbiology and Infection

Volumn 22, Issue , 2016, Pages S15-S25

  Guan, X ^a   He, L ^b   Hu, B ^b   Hu, J ^c   Huang, X ^d   Lai, G ^e   Li, Y ^f   Liu, Y ^g   Ni, Y ^h   Qiu, H ⁱ   Shao, Z ^j   Shi, Y ^k   Wang, M ^l   Wang, R ^g   Wu, D ^m   Xie, C ^a   Xu, Y ⁿ   Yang, F ^l   Yu, K ^o   Yu, Y ^p   Zhang, J ^l   Zhuo, C ^f   more..

^a SUN YAT SEN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e FUZHOU GENERAL HOSPITAL   (China)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

^g CHINESE PLA GENERAL HOSPITAL   (China)

^h SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁱ SOUTHEAST UNIVERSITY   (China)

^j TIANJIN MEDICAL UNIVERSITY   (China)

^k NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^l FUDAN UNIVERSITY   (China)

^m THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

ⁿ PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^o HARBIN MEDICAL UNIVERSITY   (China)

^p ZHEJIANG UNIVERSITY   (China)

more..

Author keywords

Enterobacteriaceae infection; Multidrug resistant (MDR); Pandrug resistant (PDR); XDR; XDR Acinetobacter infection; XDR Pseudomonas aeruginosa infection

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFOPERAZONE PLUS SULBACTAM; COLISTIN; COTRIMOXAZOLE; POLYMYXIN; QUINOLONE DERIVATIVE; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; DISINFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EXTENSIVELY DRUG RESISTANT GRAM NEGATIVE BACILLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HAND WASHING; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; LABORATORY DIAGNOSIS; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; CHINA; CLASSIFICATION; CONSENSUS; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; CHINA; CONSENSUS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84961190204     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.11.004     Document Type: Article

References (76)

1. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
2. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement 2013, CLSI document M100-S23, Clinical and Laboratory Standards Institute, Wayne, PA.
3. Jones R.N., Barry A.L., Packer R.R., Gregory W.W., Thornsberry C. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination. J Clin Microbiol 1987, 25:1725-1729.
4. Santino I., Bono S., Nuccitelli A., Martinelli D., Petrucci C., Alari A. Microbiological and molecular characterization of extreme drug-resistant carbapenemase-producing Klebsiella pneumoniae isolates. Int J Immunopathol Pharmacol 2013, 26:785-790.
5. Toth A., Damjanova I., Puskas E., Jánvári L., Farkas M., Dobák A., et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 2010, 29:765-769.
6. Naparstek L., Carmeli Y., Chmelnitsky I., Banin E., Navon-Venezia S. Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of Klebsiella pneumoniae. J Hosp Infect 2012, 81:15-19.
7. Clancy C.J., Chen L., Shields R.K., Zhao Y., Cheng S., Chavda K.D., et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013, 13:2619-2633.
8. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
9. Zarrilli R., Pournaras S., Giannouli M., Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 2013, 41:11-19.
10. Zavascki A.P., Carvalhaes C.G., Picao R.C., Gales A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010, 8:71-93.
11. Alvarez-Ortega C., Wiegand I., Olivares J., Hancock R.E., Martinez J.L. The intrinsic resistome of Pseudomonas aeruginosa to beta-lactams. Virulence 2011, 2:144-146.
12. Sanchez M.B., Hernandez A., Martinez J.L. Stenotrophomonas maltophilia drug resistance. Future Microbiol 2009, 4:655-660.
13. Brooke J.S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012, 25:2-41.
14. Hu F.P., Zhu D.M., Wang F., Jiang X.F., Xu Y.C., Zhang X.J., et al. CHINET 2014 surveillance of bacterial resistance in China. Chin J Infect Chemother 2015, 15:401-410.
15. Hu F.P., Zhu D.M., Wang F., Jiang X.F., Xu Y.C., Zhang X.J., et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016, 22(Suppl. 1):S9-S14.
16. Xu A., Zheng B., Xu Y.C., Huang Z.G., Zhong N.S., Zhuo C. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect 2016, 22(Suppl. 1):S1-S8.
17. Souli M., Galanti I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13(47). pii: 19045.
18. Liebana E., Carattoli A., Cogue T.M., Hasman H., Magiorakos A.P., Mevius D., et al. Public health risks of enterobacterial isolates producing extended-spectrum β-lactamases or AmpC β-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. Clin Infect Dis 2013, 56:1030-1037.
19. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
20. Tumbarello M., Trecarichi E.M., Tumietto F., Del Bono V., De Rosa F.G., Bassetti M., et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014, 58:3514-3520.
21. Liu Y.N., Cao B., Wang H., Chen L.A., She D.Y., Zhao T.M., et al. Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities. Zhonghua Jie He He Hu Xi Za Zhi 2012, 35:739-746.
22. Li Y., Guo Q., Wang P., Zhu D., Ye X., Wu S., et al. Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 β-lactamase at a teaching hospital in Shanghai, China. J Microbiol Immunol Infect 2015, 48:101-108.
23. Wei S.Q., Zhao Z.W., Zhong W.N., Zhao Z.X., Ye H.F., Chen H.L., et al. A case-control study on the risk factors of pandrug-resistant Pseudomonas aeruginosa pneumonia. Zhonghua Yi Yuan Gan Ran Xue Za Zhi 2009, 19:673-676.
24. Pena C., Gomez-Zorrilla S., Suarez C., Dominguez M.A., Tubau F., Arch O., et al. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis 2012, 31:2791-2797.
25. Tan C.K., Liaw S.J., Yu C.J., Teng L.J., Hsueh P.R. Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. Diagn Microbiol Infect Dis 2008, 60:205-210.
26. Safdar A., Rolston K.V. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007, 45:1602-1609.
27. Pien C.J., Kuo H.Y., Chang S.W., Chen P.R., Yeh H.W., Liu C.C., et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. J Microbiol Immunol Infect 2013, pii:S1684-S1182.
28. Paul M., Carmeli Y., Durante-Mangoni E., Mouton J.W., Tacconelli E., Theuretzbacher U., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014, 69:2305-2309.
29. Obritsch M.D., Fish D.N., MacLaren R., Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005, 25:1353-1364.
30. Lim T.P., Lee W., Tan T.Y., Sasikala S., Teo J., Hsu L.Y., et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 2011, 6:e28177.
31. Yang J.J., Sun T.Y., Hu Y.J. Multiple combination bactericidal testing against pandrug resistant Pseudomonas aeruginosa. Chin J Infect Chemother 2010, 10:357-362.
32. Sheng W.H., Wang J.T., Li S.Y., Lin Y.C., Cheng A., Chen Y.C., et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011, 70:380-386.
33. Daikos G.L., Tsaousi S., Tzouvelekis L.S., Anyfantis I., Psichogiou M., Argyropoulou A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014, 58:2322-2328.
34. Tumbarello M., Trecarichi1 E.M., De Rosa F.G., Giannella M., Giacobbe D.R., Bassetti M., et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015, 70:2133-2143.
35. Tumbarello M., Viale P., Viscoli C., Trecarichi E.M., Tumietto F., Marchese A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-950.
36. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141.
37. Sun Y., Wang L., Li J., Zhao C., Zhao J., Liu M., et al. Synergistic efficacy of meropenem and rifampicin in a murine model of sepsis caused by multidrug-resistant Acinetobacter baumannii. Eur J Pharmacol 2014, 729:116-122.
38. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Mavromanolakis E., Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010, 35:240-243.
39. Jiang Y., Shen P., Wei Z., Liu L., He F., Shi K., et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents 2015, 45:66-70.
40. Pontikis K., Karaiskos I., Bastani S., Dimopoulos G., Kalogirou M., Katsiari M., et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014, 43:52-59.
41. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069-1077.
42. Liang W., Liu X.F., Huang J., Zhu D.M., Li J., Zhang J. Activities of colistin-andminocycline-based combinations against extensive drug resistant Acinetobacterbaumannii isolates from intensive care unit patients. BMC Infect Dis 2011, 11:109.
43. Liu L.F., Li D., Chu Y.Z., Chen B.Y. In vitro activities of polymyxin B in combination with other antimicrobials against pan-drug-resistant strains of Pseudomonas aeruginosa. Chin J Antibiot 2012, 37:524-527.
44. Sader H.S., Jones R.N. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005, 25:95-109.
45. Abbott I.J., Slavin M.A., Turnidge J.D., Thursky K.A., Worth L.J. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 2011, 9:471-488.
46. Milne K.E., Gould I.M. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother 2012, 56:4071-4077.
47. Cai Y., Chai D., Wang R., Liang B., Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012, 67:1607-1615.
48. Cai Y., Li R., Liang B., Bai N., Liu Y., Wang R. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:3998-3999.
49. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
50. Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015, 15:225-234.
51. Looney W.J., Narita M., Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009, 9:312-323.
52. Wen Y.K., Cao M., Zou L., Luo Y.P., Sun B.J. In vitro combination antimicrobial susceptibility testing on carbapenem-resistant Pseudomonas aeruginosa. Chin J Antibiot 2012, 37:536-538.
53. Zhu D.M., Zhang Y.Y., Wang F. Surveillance of bacterial resistance in Shanghai hospitals during 2006. Chin J Infect Chemother 2007, 7:393-399.
54. Ji J., Du X., Chen Y., Fu Y., Wang H., Yu Y. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents 2013, 41:400-401.
55. Pei G., Mao Y., Sun Y. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii. Microb Drug Resist 2012, 18:574-577.
56. Shi Y., Xu Y.C., Liu Y., Du W., Rui X., Wang Y. Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections. Zhonghua Yi Xue Za Zhi 2012, 92:2847-2850.
57. Sader H.S., Flamm R.K., Jones R.N. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis 2013, 76:217-221.
58. Sun Y., Cai Y., Liu X., Bai N., Liang B., Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013, 41:110-116.
59. Entenza J.M., Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009, 34:1-9.
60. Falagas M.E., Vardakas K.Z., Tsiveriotis K.P., Triarides N.A., Tansarli G.S. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014, 44:1-7.
61. Ramirez J., Dartois N., Gandjini H., Yan J.L., Korth-Bradley J., McGovern P.C. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013, 57:1756-1762.
62. De Pascale G., Montini L., Pennisi M., Bernini V., Maviglia R., Bello G., et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014, 18:R90.
63. Garnacho-Montero J., Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010, 23:332-339.
64. Durante-Mangoni E., Signoriello G., Andini R., Mattei A., De Cristoforo M., Murino P., et al. Colistin and rifampicin compared with colistion alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013, 57:349-358.
65. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
66. Zhanel G.G., Lawson C.D., Adam H., Schweizer F., Zelenitsky S., Lagacé-Wiens P.R., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013, 73:159-177.
67. Lucasti C., Popescu I., Ramesh M.K., Lipka J., Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 2013, 68:1183-1192.
68. Zhanel G.G., Chung P., Adam H., Zelenitsky S., Denisuik A., Schweizer F., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014, 74:31-51.
69. Lucasti C., Hershberger E., Miller B., Yankelev S., Steenbergen J., Friedland I., et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014, 58:5350-5357.
70. Centers for Disease Control and Prevention (CDC) Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009, 58:256-260.
71. Tacconelli E., Cataldo M.A., Dancer S.J., De Angelis G., Falcone M., Frank U., et al. ESCMID guidelines for the management of the infection control measure to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014, 20(Suppl. 1):1-55.
72. Srinivasan A., Patel J.B. Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008, 29:1107-1109.
73. O'Fallon E., Gautam S., D'Agata E.M. Colonization with multidrug-resistant Gram-negative bacteria: prolonged duration and frequent cocolonization. Clin Infect Dis 2009, 48:1375-1381.
74. Climo M.W., Yokoe D.S., Warren D.K., Perl T.M., Bolon M., Herwaldt L.A., et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013, 368:533-542.
75. Munoz-Price L.S., Hota B., Stemer A., Weinstein R.A. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009, 30:1031-1035.
76. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional proGram to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.